CA
NZ
UK
AU
IND
US
Product revenue was $946 million versus $927 million, while service and other revenue was $183 million versus $157 million, which is about 17% higher on a calculated basis. Chief Executive Jacob Thaysen pointed to healthy clinicalDemandand strong NovaSeq X placements as the drivers of …
Research and development expense was $20.7 million, up $9.9 million from $10.9 million a year earlier. Direct spending on atebimetinib was $13.6 million against $5.1 million, and the company attributed $8.5 million of the increase to running the MAPKeeper 301 trial.
Orders were the stronger number. Reported orders came in at $2,345 million, up 21%, with organic orders up 18%. Chairman and CEO Vicente Reynal described an improvedDemandenvironment, with healthy activity across geographies and end markets.
Net sales were $15,220 million, up from $12,604 million, an increase of 20.8% that came from growth in every region. Advanced Solutions rose 40%, Client and Endpoint Solutions rose 10%, Cloud-based Solutions rose 31% and Other services rose 35%. The 2025 sale of the …
Revenue was $265.1 million, up from $244.9 million in the second quarter and $240.0 million in the third quarter of 2025. On a calculated basis, that is growth of about 8.2% sequentially and 10.4% year over year.
Intel Products revenue grew 22%, led by theData Centerand AI group, where revenue rose 78% to $7.3 billion on a richer mix of premium products and, to a lesser extent, demand-based pricing actions. Client Computing revenue was $8.1 billion, down 5% because of lower …
The swing came from other income. Total other loss was $124.4 million, built from a $402.1 million loss on investments that was partly offset by a $277.7 million gain on derivative instruments. The CEO said financial conditions tightened as investors priced in more Federal …
Net income was a record $6.6 million, or $0.86 per diluted share, compared with $5.2 million, or $0.71, in the third quarter of 2025. That included after-tax expenses of $657,000 tied to the proposed Grand River Commerce acquisition.
Medical device sales were $17.4 million, up 21% from $14.4 million, and now make up 85% of the total versus 77%. Orthopedic sales rose 16% to $12.8 million, mainly on the next generation handpiece sold to the largest customer. CMF sales jumped 39% to …
Net productRevenuewas $275.9 million versus $131.0 million, driven by a $162.3 million increase in Sephience, which treats phenylketonuria.Royaltyrevenue rose 15% to $81.7 million on higher Evrysdi sales, while collaboration and license revenue fell to $0.2 million from $9.3 million.
Please wait processing your request...